ArriVent BioPharma, Inc.
AVBP
$29.79
-$0.49-1.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.82% | -20.46% | -3.48% | -11.36% | 51.53% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.57% | 700.98% | -82.38% | 11.93% | 37.30% |
| Change in Net Operating Assets | 218.98% | -174.58% | 203.40% | -330.96% | 133.33% |
| Cash from Operations | 5.52% | -36.64% | 14.36% | -37.03% | 61.59% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,186.21% | 105.03% | -40.27% | -464.92% | -62.22% |
| Cash from Investing | 1,186.21% | 105.03% | -40.27% | -464.92% | -62.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.89% | 57.94% | -59.68% | 14.25% | 1,007.61% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -105.67% | 199.01% | -506.00% |
| Cash from Financing | 56.89% | 58.02% | -59.84% | 15.11% | 1,011.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 458.95% | 124.67% | -72,084.95% | -100.15% | 357.49% |